-
Tongluo Mingmu Capsules Approved for Marketing by China NMPA
2023-10-19
Recently, the Category 1.1 innovative traditional Chinese medicine Tongluo Mingmu Capsules of Shijiazhuang Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Ritlecitinib Tosylate Capsules Approved for Marketing
2023-10-19
Recently, the Category 1 innovative drug Ritlecitinib Tosylate Capsules (trade name: LITFULO ®) of Pfizer Inc. is approved for marketing through priority review and approval procedures by China NMPA.
-
Deucravacitinib Tablets Approved for Marketing by China NMPA
2023-10-19
Recently, the category 1 innovative product Deucravacitinib Tablets (trade name: Sotyktu) of Bristol Myers Squibb is approve for marketing by China NMPA.
-
NMPA Becomes the Applicant for PIC/S
2023-11-09
In late September 2023, the National Medical Products Administration(NMPA) submitted formal application to the Pharmaceutical Inspection Co-operation Scheme (PIC/S).
-
NMPA Held 2023 ICH in China: Progress and Outlook Symposium
2023-09-13
On September 12, NMPA held 2023 ICH in China: Progress and Outlook Symposium in Beijing, to make dialogue on development and cooperation with representatives from domestic and foreign industry associations.
-
Narlumosbart Injection Approved with Conditions for Marketing by China NMPA
2023-09-06
Recently, the Narlumosbart Injection (Chinese trade name: 津立生) of Shanghai JMT Biological Technology Co. Ltd. is approved with conditions through the priority review and approval procedure by China NMPA.
